ME-344 shows enhanced anti-tumour activity in combination with tyrosine-kinase inhibitor in preclinical studies
6 May 2015 | By Victoria White
MEI Pharma has announced new preclinical data showing mitochondria-specific effects of the Company's investigational drug candidate ME-344 in cancer cells...